Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-week vs conventional chemoradiotherapy in rectal cancer
NCT02484040Phase 3Unknown
- Start
- Dec 2015
- Primary completion
- Jul 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in rectal cancer. Status: unknown.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02484040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484040.